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Abstract 
Introduction 
Membranous nephropathy (MN) is a major immune complex-mediated 
glomerulonephritis (ICGN) and can be grouped into idiopathic (primary) type and 
secondary type of MN in human.  
Phospholipase A2 receptor (PLA2R) is expressed in the glomerular podocytes of 
human kidney. Anti-PLA2R autoantibodies were discovered in the majority of patients 
with idiopathic MN. Also, enhanced glomerular expression of PLA2R is reported in 
most patients of the disease. Therefore, PLA2R is suggested to be causative autoantigen 
of human idiopathic MN. On the other hands, PLA2R is expressed minimal or absent in 
murine and rat podocytes. Because a suitable animal model of PLA2R -associated 
glomerular disease has not been established, the function of this receptor in podocytes, 
and whether the circulating autoantibodies actually bind PLA2R on podocytes, remains 
unclear. 
In dogs, MN is a major spontaneous glomerular disease and its histological and 
clinical characteristics are analogous to idiopathic MN in humans. However, there are 
no reports describing the expression of PLA2R in canine podocytes, and the 
pathogenesis of canine MN has not been investigated. In this study, the author 
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hypothesized that some case of canine MN might be induced by the autoimmune 
mechanism in common with human idiopathic MN. 
Chapter 1 
Human MN can be grouped into idiopathic (primary) type and secondary type. In 
electron microscopy, the dense deposits are usually limited in subepithelial area in 
idiopathic MN, while these are observed also in subendothelial and mesangial area in 
addition to subepithelial area in secondary MN. In this chapter, the author investigated 
the localization of immune deposits in 8 cases of MN dogs by electron microscopy.  In 
4 cases, the deposits were limitedly observed in subepithelial area. In another 4 cases, 
subendothelial and mesangial deposition was also observed. In this study, the author 
demonstrated some cases of canine MN exhibiting restrictive subepithelial localization 
of dense deposits, which is consistent with characteristic finding in human idiopathic 
MN.  
Chapter 2 
In this chapter the author performed gene cloning and motif analysis for canine PLA2R 
obtained from normal glomeruli and investigated the expression and detailed 
localization of PLA2R in normal glomeruli and a MN cases dogs by 
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immunofluorescence (IF). The author provided fundamental information that canine 
PLA2R obtained has high homology and common extracellular structures with human 
PLA2R.  In addition to expression of PLA2R in normal glomeruli, the author 
demonstrated increased expression of PLA2R in some cases of MN dog showing 
idiopathic deposition pattern in chapter 1. Similar altered expression of PLA2R was 
reported in human idiopathic MN, in association with the presence of serum anti- 
PLA2R auto-antibody. The results in this chapter may support the author’s hypothesis 
that some canine MN cases may be autoimmune mechanism associated with PLA2R as 
an autoantigen expressed in podocyte. 
Chapter 3 
In the previous chapter, the author revealed glomerular expression of PLA2R in dogs. 
The object in this chapter is to establish the method of podocyte primary culture for 
dogs and to confirm the expression of PLA2R in the canine cultured podocyte. The 
author succeeded in effective isolation of glomeruli from canine kidney by modifying 
the method for rat. Canine cultured podocytes in the present study distinctly expressed 
PLA2R in addition to several podocyte-specific markers, including nephrin, podocin and 
synaptopodin. The podocyte expression of PLA2R was confirmed by reverse 
transcriptase polymerase chain reaction, western blotting and IF in dogs. The in-vitro 
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experiment provided from this method may contribute to progression of investigation 
for canine glomerular disease including MN. 
Conclusion 
In this study, the author revealed new findings on ultrastructural feature of canine MN 
and PLA2R expression in glomerular podocytes of dogs as follows.  
1. Canine MN showed two different deposition patterns of dense deposit in the 
glomeruli resembling human idiopathic or secondary MN. This may suggest the 
presence of different pathogenesis in canine MN as suspected in human MN. 
2. Canine PLA2R obtained from the glomeruli has high homology and common 
extracellular structures with human PLA2R.  
3. Canine PLA2R is expressed in podocyte and distributed on the foot process in tissue 
sections. This is important finding suggesting the possibility of dogs as an animal model 
of human idiopathic MN. Because PLA2R is not expressed in the podocytes of rodents, 
rabbits and no experimental or spontaneous animal models for idiopathic MN have been 
established, so far.  
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4. The increased expression of PLA2R, which is feature of human idiopathic MN 
associated with PLA2R, demonstrated in some of MN dog cases with idiopathic 
ultrastructural pattern of dense deposit. These results may support the author’s 
hypothesis that some canine MN cases are autoimmune disease associated with PLA2R 
as an autoantigen expressed in podocyte. 
5. The primary culture method for canine podocyte expressed several podocyte specific 
proteins was established. The in vitro experiment provided from this method may 
contribute to progression of investigation for canine glomerular disease including MN. 
These results may support the author’s hypothesis that some canine MN cases are 
autoimmune disease associated with PLA2R as an autoantigen expressed in podocyte. In 
addition, the author established the primary culture method for canine podocyte. The in 
vitro experiment provided from this method may contribute to progression of 
investigation for canine glomerular disease including MN. 
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General Introduction 
Membranous nephropathy (MN) is a major immune complex-mediated 
glomerulonephritis (ICGN) in both dogs and human, and characterized by the 
subepithelial formation of immune deposits containing immunoglobulin (Ig) G and 
complement components causing subsequent podocyte injury and glomerular basement 
membrane (GBM) changes in the glomeruli [8, 25].  
In human medicine, MN can be grouped into idiopathic (primary) type and secondary 
type of MN by presence of underlying disease and histopathological feature for each 
type. In clinical strategy, differentiation of these types is very important, because the 
patients with secondary MN require detection and therapy of underlying disease, such 
as infection (hepatitis B), systemic autoimmune disease, medications or chemical 
exposures (NSAIDs, mercury), and certain malignancies [3, 33]. In pathogenesis, the 
different mechanisms of the subepithelial formation of immune deposits are assumed in 
each type of MN. The evidences in many recent reports suggested in situ immune 
complex (IC) formation in human idiopathic MN. A primary form of MN was reported 
in neonates born from mothers with defect of neutral endopeptidase (NEP) localized on 
podocytes cell membrane and having anti-NEP antibodies sensitized during previous 
pregnancies [3, 33]. Also, a well-known rat model of idiopathic MN, Heymann’s 
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nephritis was first described in the rats injected with kidney extracts resulting in 
nephrotic syndrome in 1959 [19]. Thereafter, megalin was identified as a target protein 
in Heymann’s nephritis which is expressed in both the brush border of proximal tubular 
cells and podocyte foot processes [13]. At the present day, Heymann’s nephritis can be 
induced by immunization with rat proximal tubule brush borders fraction termed Fx1A 
(active Heymann’s nephritis) or injection of anti- Fx1A antibody produced in other 
animals (passive Heymann’s nephritis) [27]. Despite of these evidences, the podocyte 
antigens in most of idiopathic MN had not been identified. Recently, the expression of 
phospholipase A2 receptor (PLA2R) on glomerular podocytes in the human kidney was 
demonstrated and anti-PLA2R autoantibodies were discovered in the majority of 
patients with idiopathic MN [2,  18, 36, 39]. 
Phospholipase A2 (PLA2) is a family of lipolytic enzymes and hydrolyzes the sn-2 
position of phospholipids to generate the corresponding fatty acid and lysophospholipid 
[11, 16]. Also, PLA2 relate to generate various types of biologically active lipids, 
including prostaglandins hydroxy fatty acids, leukotrienes, thromboxanes, and platelet-
activating factor [11, 16].  Secretory PLA2 (sPLA2) are a group of low molecular weight 
(~14 kDa) and secreted from cells. To date, there are 10 type of  mammalian sPLA2 
classified as groups IB, IIA, IIC, IID, IIE, IIF, III, V, X and XII. The sPLA2-IB is a 
10 
 
most major enzyme and provided the fundamental information on structure and 
mechanism. sPLA2-IB, as a ligands, induces various biological processes such as cell 
proliferation, cell migration, hormone release, and eicosanoid production in various 
cells and tissues [9, 15, 16] mediated by PLA2R, a type I transmembrane glycoprotein 
related to the C-type animal lectin family receptor. Studies using PLA2R-knockout mice 
have demonstrated a critical role of PLA2R in the regulation of the development of 
endotoxic shock [14]. 
Subsequent to the discovery of anti-PLA2R autoantibodies, PLA2R was highlighted as 
a causative antigen located on podocytes in human idiopathic MN and many clinical 
studies have been reported. For example, the prevalence of elevated anti-PLA2R 
autoantibody levels was reported in several countries [2, 18, 36, 39] and autoantibody 
titer was found to be strongly associated with disease activity and proteinuria in 
idiopathic MN patients [21]. In addition, the enhanced expression of PLA2R was 
histologically observed in the glomeruli of idiopathic MN patient and the 
immunostaining for PLA2R in biopsy samples is thought to be alternative method for 
diagnosis of idiopathic MN associating with anti- PLA2R antibody [23, 40, 43]. 
However, basic research to elucidate the pathogenesis of PLA2R associated MN has 
not been expanded, while these are many clinical studies as described above. In general, 
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the establishment of a suitable animal model and experimental reproduction of the 
disease is critical to understanding the pathogenesis of autoimmune diseases. However, 
the expression of PLA2R in the glomerular podocytes was found to be minimal or 
absent in mice and rats [4, 6, 37, 43] and to date, a suitable animal model of PLA2R -
associated glomerular disease has not been established. Due to the lack of an animal 
model, the function of this receptor in podocytes, and whether the circulating 
autoantibodies actually bind PLA2R on podocytes, remains unclear. 
In dogs, glomerular diseases are thought to be the common cause of chronic renal 
failure [32]. And it has been reported that canine glomerular diseases share many of the 
histological characteristics seen in their human counterparts [7, 8, 25, 31].  To develop a 
comprehensive understanding of canine glomerular disease, the World Small Animal 
Veterinary Association–Renal Standardization Study Group (WSAV-ARSSG) was 
conceived at Netherland’s Utrecht University in January 2005. They makes a diagnosis 
based on the World Health Organization classification system for human glomerular 
disease by routinely using standardized light microscopy (LM), immunofluorescence 
(IF), and transmission electron microscopy (TEM) methods [7, 8, 25, 31]. Canine 
glomerular diseases are divided into three broad categories including amyloidosis, 
ICGN, and non-ICGN.  Canine MN is a representative ICGN as well as 
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membranoproliferative glomerulonephritis (MPGN) and accounts for about 30% of 
canine glomerular diseases [7, 8, 25, 31] and has following features; diffuse thickening 
of the glomerular walls without endocapillary hypercellularity (LM), granular 
deposition of Igs and compliments along the glomerular walls (IF), subepithelial 
depositions of dense deposits (TEM) and severe proteinuria (clinical feature).  
As described above, because canine MN has high incidence in canine glomerular 
diseases and similarities to human MN, the elucidation of the pathogenesis canine MN 
could contribute not only to veterinary medicine but also to human medicine. However, 
there are no reports regarding the expression of PLA2R in canine podocytes, and the 
pathogenesis of canine MN has not been investigated.  
In veterinary medicine, several researchers have investigated canine glomeruli using 
histologic sections. They showed normal expression of some podocyte specific markers 
and altered expression in various glomerular diseases in common with human and 
experimental animals [24, 30]. Podocyte cell culture derived from human, mice and rat 
glomeruli has been used in many studies aimed for elucidating their physiological and 
pathophysiological characteristics. However, there is no in vitro research using canine 
cultured glomerular podocytes because of the lack of culture methods for canine 
podocytes. 
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In this study, the author hypothesized that some cases of canine MN might be 
induced by the autoimmune pathogenesis in common with human idiopathic MN. 
Therefore, in chapter 1, the author demonstrated ultrastructural features in canine MN 
focusing on distribution of dense deposits in the glomeruli which suggested the 
mechanism of the subepithelial formation of immune deposits.  In chapter 2, the author 
revealed fundamental information of canine PLA2R and shown normal expression of 
PLA2R in the glomeruli and also increased expression of that some canine MN cases 
exhibited ultrastructural feature of the glomerulus consistent with human idiopathic MN 
associating with PLA2R. In chapter 3, the author showed the method of primary 
cultured for canine podocytes and the distinct expression of PLA2R in canine cultured 
podocyte to confirm in vivo study on the expression of PLA2R in the normal and 
affected glomeruli.  
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Chapter 1 
 
Ultrastructural features of canine membranous nephropathy with 
special reference to distribution of dense deposits in the glomeruli 
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Introduction 
In dogs, MN is a major spontaneous glomerular disease and its histological and 
clinical characteristics are analogous to idiopathic MN in humans [7, 8, 25, 31]. 
In human medicine, MN can be grouped into idiopathic (primary) type and secondary 
type of MN. This distinction is thought to be important because clinical behavior and 
therapeutic strategy are different in both types. The most important point to confirm 
idiopathic MN is lack of features suggestive of underlying disease leading secondary 
MN, such as infection (hepatitis B), systemic autoimmune disease, medications or 
chemical exposures (NSAIDs, mercury), and certain malignancies and so on [3, 33]. 
However, the light microscopic feature of idiopathic and secondary MN is similar or 
even identical and the clinical distinction is difficult when the underlying disease is 
unclear. On the other hands, some pathological changes suggestive of idiopathic or 
secondary MN are often observed. For instance, IgG subclass containing in IC is mainly 
IgG4 in idiopathic MN [3, 33]. In ultrastructural feature, the dense deposits are usually 
limited in subepithelial area in idiopathic MN, while these are observed also in 
subendothelial and mesangial area in addition to subepithelial area in secondary MN 
[33]. 
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On the other hands, the difference of deposition patterns associated with pathogenesis 
has not been described in canine MN. Therefore, in this chapter, the author investigated 
the localization of immune deposits in MN dogs.   
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Materials and Methods 
Renal Biopsies cases 
The clinical data and pathologic diagnosis of dogs employed in the present study is 
shown in Table 1. The glomerular diseases cases using in the study include eight MN 
(No. 1 to 8), two MPGN (No. 9 and 10) and two non-ICGN (No. 11 and 12) cases.  
These biopsies were surgically carried out using 16 or 18-gauge Tru-cut-type needles 
by opening the abdominal cavity of the dogs. One third of biopsy tissue was fixed in 
10% neutral-buffered formalin for histological examination, another one third was fixed 
in 2.5% glutaraldehyde for TEM and last one third was embedded in optimal cutting 
temperature (OCT) compound (Sakura Finetek, Tokyo, Japan) for IF, and block 
embedded in OCT compound was snap-frozen and kept at -80 °C. The pathological 
diagnosis was made based on the light and electron microscopic changes and immune 
deposition pattern. In all biopsy, Over 10 glomeruli were observed for histological 
diagnosis on LM. The World Health Organization’s classifications of human glomerular 
diseases were consulted [33].  
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Immunofluorescence (IF) 
Immune deposition in glomeruli were evidenced by direct IF using antibodies of anti-
dog IgG fluorescein isothiocyanate (FITC) conjugated (Cappel, Aurora, Ohio, 1:500 
dilution), dog C3 antibody FITC conjugated (Bethyl, 1:500 dilution), dog IgA antibody 
FITC conjugated (Bethyl, Montgomery, TX, 1:200 dilution) and dog IgM antibody 
FITC conjugated (Bethyl, 1:1000 dilution) for frozen sections. 
 
Ultrastructural analysis 
To observe deposition of IC, a small piece from biopsy tissue was cut into 1-mm
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cubes, fixed in 2.5% glutaraldehyde and post-fixed in 1% OsO4 for 2 hr. The fixed 
specimens were then dehydrated through ascending grades of alcohol and embedded in 
epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate and a 
JEOL 1210 transmission electron microscope (JOEL, Tokyo, Japan) at 80 kV was used 
for examination. Two or more of glomerulus were observed in each case. The staging 
(stage I-IV) were according to human staging system for MN [33].  The deposition 
patterns of dense deposit were grouped by “restrictive subepithelial deposition” or 
“subepithelial deposition accompanied by subendothelial and/or mesangial depositions” 
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Results 
Light and fluorescence microscopic findings of membranous nephropathy 
Light microscopically, this disease is characterized by diffuse thickening of the 
glomerular walls without cellar proliferation. Consistent with this thickening, granular 
deposition of Igs and compliment is detected by IF. And clinically, severe proteinuria 
was observed in most of dogs (Table 1).  
 
Deposition pattern of immune complexes in Canine MN 
The deposition pattern of each case was shown in Table 1. In 4 cases, from No.1 to No. 
4, the deposits were limitedly observed in subepithelial area (Fig. 1). In another 4 cases, 
from No.5 to No.8, subendothelial and mesangial deposition was also observed. 
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Discussion 
In this chapter, the author demonstrated some cases of canine MN exhibiting 
restrictive subepithelial localization of dense deposits, which is a characteristic finding 
in human idiopathic MN.  
Similar deposition pattern was observed in human neonatal MN. This disease is 
reported in neonates born from mothers with defect of NEP localized on podocytes cell 
membrane and having anti-NEP antibodies sensitized during previous pregnancies [10].  
Also, a representative experimental model of idiopathic MN, Heymann’s nephritis was 
caused by binding of circling antibodies to an antigen, called as megalin, expressed on 
podocyte cell membrane [19, 27]. Recently, autoantibody against PLA2R, a protein on 
podocyte cell surface, was discovered in the majority of patients with idiopathic MN [2], 
thereafter PLA2R was highlighted as a candidate antigen composing IC deposited in the 
glomeruli of idiopathic MN. 
In this manner, many evidences in previous reports suggested that this deposition 
pattern indicated autoimmune mechanisms against antigens on podocyte cell membrane 
causing in situ formation of IC, although the glomerular deposition of circulating 
antigen-antibody complex in serum is considered as mechanisms of IC deposition in the 
secondary MN glomeruli. 
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Therefore, canine MN cases showing idiopathic deposition pattern observed in this 
study may have autoimmune pathogenesis in common with human idiopathic MN 
associated with autoantigens on podocyte like PLA2R. 
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Figures and Tables 
 
Table 1. The clinical data, pathological diagnosis of dogs and the results of analysis in 
this study. 
 
 
 
 
 
 
Sex/Age Urinary
(years) Protein Stage Deposition pattern
1
Miniature 
dachshund
Cas/6 9.3 I
2 Boston terrier Sp/10 4.6 III-IV
3
Miniature 
dachshund
F/10 2.8 I
4 Yorkshire terrier F/8 1.4 II
5 Papillon Cas/12 2.2 II-III Subepithelial NA
6 Lhasa apso Sp/12 3+(strip) I ＋
7 Yorkshire terrier Sp/8 5.1  III-IV
Subendothelial and 
mesangial deposition
8 French bulldog M/10 12.64 III
9 Yorkshire terrier F/5 12.84
10  Toy poodle F/5 3.5
11 Italian greyhound Sp/6 9.5
12 Shetland Sheepdog M/8 7.66
M: Male, F: Female, Cas: Castrated, Sp: Spayed, Urinary Protein: Urinary protein/creatinin ratio or reagent strip, MN: 
membranous nephropathy, MPGN: membranoproliferative glomerulonehritis, NIMGN: Non-immune-mediated 
glomerulonehropathy, NA: not available
MPGN
Subepithelial, Subendothelial 
and mesangial region
No
NIMGN Non No
MN
NA
Yes
No
Subepithelial deposition
No.
Pthological 
diagnosis
Breeds
Immunocomplexes Enhanced 
expression of 
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Fig. 1.  Transmission electron microscopy of the glomerulus in canine MN.  
The dense deposits were limitedly observed in subepithelial area along capillary walls 
in upper 2 cases (No. 1 and No. 2). The dense deposits were also observed in 
subendothelial and mesangial area in lower two. Arrowheads: dens deposit in 
subepithelial area, Asterisk: dens deposits in subendothelial area. TEM. 
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Chapter 2 
 
Expression of phospholipase A2 receptor in normal glomerulus 
and membranous nephropathy in dogs 
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Introduction 
In chapter 1, the author demonstrated that some canine MN cases have characteristic 
ultrastructural features seen in human idiopathic MN. Therefore, in this chapter the 
author focused on a new candidate autoantigen, PLA2R, probably associated with 
human idiopathic MN.  
PLA2R is a type I transmembrane glycoprotein related to the C-type animal lectin 
family [16] and is reported to mediate various biological processes, such as cell 
proliferation, cell migration, hormone release, and eicosanoid production via s PLA2 
(ligand of PLA2R) stimulation in various cells and tissues [9, 15] . 
Recently, the expression of PLA2R on glomerular podocytes in the human kidney was 
demonstrated and anti-PLA2R autoantibodies were discovered in the majority of 
patients with idiopathic MN [2]. Subsequent to this report, PLA2R was highlighted as a 
causative antigen located on podocytes in human idiopathic MN and many clinical 
studies have been reported. For example, the prevalence of elevated anti-PLA2R 
autoantibody levels was reported in several countries [2, 18, 34, 36, 39] and 
autoantibody titer was found to be strongly associated with disease activity and 
proteinuria in idiopathic MN patients [21]. In addition, the enhanced expression of 
PLA2R was histologically observed in glomeruli of idiopathic MN patient and the 
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immunostaining for PLA2R in biopsy samples is thought to be alternative method for 
diagnosis of idiopathic MN associated with anti- PLA2R antibody [23, 40, 43].   
The expression of PLA2R on glomerular podocytes has been reported in human 
kidneys, while its expression was found to be minimal or absent in mice and rats [4, 6, 
21, 37]. To date, a suitable animal model for human idiopathic MN associated with 
autoantibody against PLA2R has not been established. Due to the lack of an animal 
model, the function of this receptor in podocytes, and whether the circulating 
autoantibodies actually bind PLA2R on podocytes, remains unclear. Therefore, the 
identification of a suitable animal model is critical to understanding the pathogenesis of 
human idiopathic MN. 
In dogs, there are no reports describing the expression of PLA2R in the normal 
glomeruli, and pathogenesis of MN has not been investigated despite its high incidence.  
Here, we describe the expression and detailed localization of PLA2R in normal canine 
glomeruli and altered expression of PLA2R in dog MN cases.  
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Materials and Methods 
Animals 
Various organs (heart, lung, liver, kidney, spleen, stomach, pancreas, small intestine, 
colon, uterus, ovary, testis, brain, lymph node, renal cortex, and renal medulla) were 
obtained from 12 month-old male and female beagle dogs for reverse transcriptase 
polymerase chain reaction (RT-PCR) to see the expression of PLA2R. All dogs were 
purchased from a laboratory animal breeding and supply company (Kitayama Labes Co, 
Ltd, Nagano, Japan) and confirmed to be healthy by physical examination. The animals 
were used for clinical education and euthanized in accordance with the guidelines 
approved by the Animal Research Committee of Azabu University (No. 100408-3) 
 
Renal Biopsies cases 
Same renal Biopsies cases in this study except for three cases of MN (No. 1, 2 and 7) 
were used (summarized in Table 1 in chapter 1).  
 
Immunofluorescence  
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The primary and secondary antibodies using in this study were summarized in Table 2. 
The renal tissues were embedded in OCT compound (Sakura Finetek, Tokyo, Japan) 
and snap-frozen. Cryosections (3 µm) were made and fixed in acetone for 20 min at -
20 °C and washed with phosphate buffered saline (PBS; pH 7.2, 0.01 M). IF for PLA2R, 
cryosections were pretreated by citrate buffer (pH 6.0) at 90 °C for 10 min. Images were 
obtained using a FSX100 fluorescence microscope (OLYMPUS, Tokyo, Japan) or a 
Leica TCS SP5 confocal microscope (Leica Microsystems, Heidelberg, Germany). 
 
Isolation of glomeruli for Reverse Transcriptase Polymerase Chain Reaction 
The glomeruli were isolated from renal tissues using the sieving method as previously 
reported [42]. Briefly, renal cortical tissue was minced and sieved through 600, 250 and 
125 µm pore-size stainless-steel meshes with PBS. Finally, the glomeruli were collected 
on a 75 mm mesh and placed into a low protein binding tube (SUMILON Proteosave; 
Sumitomo Bakelite, Tokyo, Japan). 
 
Reverse Transcriptase Polymerase Chain Reaction 
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Total RNA from the isolated glomeruli and various organs was extracted using TRIzol 
reagent (Invitrogen Life Technologies, Carlsbad, California). First-strand 
complementary DNA (cDNA) libraries were obtained from the total RNA using the 
Superscript III first-strand synthesis system (Invitrogen).  
Table 3 summarizes the primer sequences used in this study. Amplification of the full 
length PLA2R sequence was accomplished using two forward primers and a reverse 
primer as follows: forward primer 1 (F1) is specific for the 5’ un-translated region 
(UTR) of feline PLA2R, which has a high degree of homology among mammals, 
forward primer 2 (F2) is specific for the 5’ terminal coding sequence (CDS) of canine 
PLA2R, and the reverse primer is specific for 3’ terminal region of the predicted mRNA 
sequence of canine PLA2R.  
PCR reactions using KOD FX Neo (Toyobo, Osaka, Japan) were performed as follows: 
denaturation at 94 °C for 2 min; 30 cycles (glyceraldehyde-3-phosphate 
dehydrogenase ; GAPDH) or 35 cycles (partial and full length PLA2R) of denaturation 
at 98 °C for 10s, annealing at 64 °C for 30s, and extension at 68 °C for 30s (partial 
PLA2R and GAPDH ) or 150s (full length PLA2R); and a final extension step at 68 °C 
for 30s.  
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Cloning and sequencing for full-length canine PLA2R 
The full-length canine PLA2R amplified from isolated glomeruli was inserted into the 
pTA2 vector according to the TArget Clone™ -Plus- protocol (Toyobo), and 
sequencing was performed at the Dragon Genomics Center (TAKARA BIO INC., Otsu, 
Japan). The forward primers utilized in sequencing PLA2R are summarized in Table 4. 
Alignment and motif analysis of the amino-acid sequence were performed using 
BLAST (Basic Local Alignment Search Tool) in NCBI. 
 
In situ hybridization 
Small piece of the canine renal tissue were fixed in 10% neutral buffered formalin and 
embedded in paraffin wax. In situ hybridization (ISH) was performed on the paraffin 
sections (4 µm) using the QuantiGene® ViewRNA ISH Tissue Assay (Affymetrix, 
Santa Clara, CA, U.S.A.) according to the manufacturer’s protocol. Gene-specific probe 
sets for canine PLA2R mRNA consisting of an average of 20 different probe pairs were 
custom designed based on the full length PLA2R sequence determined in this study, and 
synthesized by Affymetrix. The signal for PLA2R mRNA was visualized with fast red 
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and examined using differential interference contrast microscopy. An ISH reaction 
solution without the probes was used as a negative control, according to Affymetrix’s 
recommendations. 
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Results 
Alignment and motif analysis of the canine PLA2R amino-acid sequence 
Two different forward primers were employed to amplify the full-length sequence of 
canine PLA2R using RT-PCR. A single band was obtained using the F1 primer, which 
is specific for the 5’ UTR of feline PLA2R, but not when using the F2 primer, which is 
specific for the predicted 5’ terminal CDS of canine PLA2R in Genbank (Accession 
Number: XM_545489) (Fig. 2A). The full-length CDS of canine PLA2R was 
determined from the amplicon and the sequence, except for primer-binding sites, was 
registered with Genbank (Accession Number: LC049956). The amino acid sequence of 
canine PLA2R determined in this study had 1463 amino acid residues, and 34 amino 
acid residues in the N-terminal was completely different from the predicted PLA2R 
sequence in the Genbank database (Fig. 2B), whereas the subsequent amino-acid 
sequence were consistent with the predicted PLA2R sequence, except for amino acid 
1301. This single nucleotide substitution (C to T) causing missense mutation (S to F) is 
documented as a genetic variation reported in Genbank. Motif analysis demonstrated 
that canine PLA2R contains extracellular structures with an N-terminal ricin-type beta-
trefoil (RICIN), a fibronectin II-like  (FN2) domain, and eight C-type lectin-like 
(CLECT) domains in common with human PLA2R (Fig. 2C). 
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Table 5 shows the sequence comparison of PLA2R amino acids between dog and 
different animals including human (Accession Number: NP_031392), cat 
(XP_006935367), mouse (NP_032893) and rat (NP_001094307). Full sequence of 
canine PLA2R exhibited a higher degree of homology with cat and human sequence 
compared with mouse and rat.  Among all domains, CLECT domain 4 had high degree 
of homology with that of all animals. 
 
Expression of PLA2R protein and mRNA in canine renal glomeruli 
The expression of PLA2R protein and mRNA in canine renal glomeruli was 
demonstrated using IF and ISH. In the IF experiments, the labeling of PLA2R exhibited 
a podocyte pattern, that is, diffuse staining in a linear pattern along the glomerular 
capillary wall (Fig. 3A). Consistent with this result, the labeling of PLA2R mRNA in the 
ISH experiments was restricted to the glomeruli (Fig. 3C).  
 
Localization of PLA2R protein in the glomeruli 
Double IF was performed to reveal the detailed localization of PLA2R protein. PLA2R 
staining colocalized with podocin along the glomerular capillary wall (Figs. 4A to F). 
On the other hand, the labeling of PLA2R was distinct from vimentin and type IV 
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collagen, and was localized between vimentin (Figs. 5G to I) and type IV collagen (Figs. 
5J to L).  
 
Protein expression of PLA2R in the cases of glomerulonephropathy 
In 2 MN cases (No. 3, 4) showing idiopathic deposition pattern as shown in chapter 1, 
increased staining for PLA2R was observed along the glomerular capillary walls (Fig.  
5). However, this increased staining was not observed in other 3 MN cases with non-
idiopathic deposition pattern (No. 6 to 8) and other 4 glomerular diseases.  
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Discussion 
In this study, we provide fundamental information on canine PLA2R, including the 
high structural similarity to human PLA2R, mRNA tissue distribution, and detailed 
localization of the protein on glomerulus. Double IF demonstrated colocalization of 
PLA2R and podocin in the canine glomeruli. This finding suggested that canine PLA2R 
is distributed on the foot process and podocyte cell surface. 
The N-terminal sequence of the PLA2R determined in this study differs considerably 
from the predicted sequence in the two major sequence databases (NCBI and Ensemble). 
Incidentally, we could not detect any specific bands by RT-PCR using several 
additional forward primers specific for the 5’ terminal of the predicted sequence. These 
results indicate that the sequence obtained in this study, using forward primers specific 
for a highly homologous mammalian UTR, is the correct canine PLA2R sequence from 
glomeruli.  
The amino acid sequence of canine PLA2R had high homology with human and also 
cat which is one of the most popular companion animals and could be candidate of 
animal model for MN as dogs. However, there are no reports about PLA2R in cat and its 
fundamental information is unknown, for example it is expressed in the podocyte. In 
point of function, CLECT domains 3 to 5 are essential recognition regions for sPLA2-
IB (a subtype of sPLA2). Especially, the conserved sequence of CLECT domain 4, 
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observed in this study, has been reported and suggested to play an important role for 
various function induced sPLA2-IB [20]. 
In addition to expression of PLA2R in normal glomeruli, the author demonstrated 
increased expression of PLA2R in some of MN dog cases showing idiopathic deposition 
pattern in chapter 1. Similar altered expression was reported in human idiopathic MN, 
in strongly association with the presence of serum anti-PLA2R auto-antibody [23, 40, 
43]. At the present time, immunostaining for PLA2R is considered as a useful method 
for diagnosis of human idiopathic MN and can be alternative method for autoantibodies 
detection. These results may support the author’s hypothesis that some of canine MN 
cases are autoimmune disease associated with PLA2R as an autoantigen expressed in 
podocyte. 
However, so far, there are no reports to detect auto-antibody against PLA2R or other 
antigens in dogs. In human idiopathic MN, auto-antibodies to PLA2R in serums from 
patients only recognize the protein in the non-reduced state (intact disulfide bonds),   
and cannot be detected in serums from several dozen percent of idiopathic MN and 
almost all of secondary MN. In companion animals, no regard is given to pathogenesis 
of MN and differentiation between idiopathic and secondary types may not be 
concerned. Therefore, it is important future issues for certifying the presence of anti-
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PLA2R auto-antibodies in dogs to conduct a large scale research on a large number of 
MN cases and to establish detection techniques for PLA2R auto-antibodies. 
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Figures and Tables 
 
Table 2. Primary antibodies used in immunofluorescence staining 
Primary antibody 
for IF 
Clone Dilution Reference or Source Secondary antibody 
Fixation for 
immunocytology 
Goat PLA2R 
goat 
polyclonal 
1:100 
Abcam, Cambridge, United 
Kingdom 
Alexa Fluor 568-conjugated  
donkey anti-goat IgG (Invitrogen, 
Tokyo, Japan) 
Acetone 
Mouse PLA2R CL0474 1:100 
Atlas Antibodies AB, 
Stockholm, Sweden 
Alexa Fluor 568-conjugated goat 
anti-mouse IgG (Invitrogen) 
Methanol 
Vimentin V9 1:100 Dako, Glostrup, Denmark 
Alexa Fluor 488-conjugated goat 
anti-mouse IgG (Invitrogen) 
- 
Type IV collagen 
rabbit 
polyclonal 
1:100 
a gift from Dr. K. Arai, Tokyo 
University of Agriculture and 
Technology, Tokyo, Japan 
Alexa Fluor 488-conjugated goat 
anti-rabbit IgG (Invitrogen) 
- 
Podocin 
rabbit 
polyclonal 
1:100 Sigma, St Louis, Missouri 
Alexa Fluor 488-conjugated goat 
anti-rabbit IgG (Invitrogen) 
Acetone 
Canine nephrin 
rabbit 
polyclonal 
1:50 Kobayashi et al. 2012 
Alexa Fluor 488-conjugated goat 
anti-rabbit IgG (Invitrogen) 
Acetone 
von Willebrand 
factor (vWF) 
rabbit 
polyclonal 
Prediluted Dako, Glostrup, Denmark 
Alexa Fluor 488-conjugated goat 
anti-rabbit IgG (Invitrogen) 
Methanol 
Ionized calcium 
binding adaptor 
molecule 1 (Iba-1) 
rabbit 
polyclonal 
1:200 
Wako Pure Chemical 
Industries 
Ltd., Osaka, Japan 
Alexa Fluor 488-conjugated goat 
anti-rabbit IgG (Invitrogen) 
Methanol 
Synaptopodin 
goat 
polyclonal 
1:100 
Santa Cruz Biotechnology, 
Santa Cruz, California, USA 
Alexa Fluor 488-conjugated rabbit 
anti-goat IgG (Invitrogen) 
Acetone 
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Table 3. Primers used for RT–PCR used in this study
Primer sequence (5’-3’) Sequence accession Location
F1: CGAGTCCAGTGGTTAGGGATG
XM_006935305
(Predicted feline PLA2R)
153-173
F2: ATGCGTGCAGAGAGCCAGGAG 1-21
R:
GCATTCTCTGAGTTCATTGGTAT
GG
4495-4519
F: ACAGGAGAAAACGGAGCAGG 1938-1957
R: ACTCCCAAGAGCCAGCATTC 2223-2242
F: CAAAGTGCGGGTGATCGCT 984-1002
R: GGCAACCAAAGGAAGTGCAG 1353-1372
F: TCGGGTAGCAGGAAACTTGG 3781-3800
R: AAGCCACCTCCCAGAAGAGT 4043-4062
F: ACCCCATGGACTCAACGAAG 223-242
R: GGCCCAACGCTGGTTTCTG 581-599
F: CTGAACGGGAAGCTCACTGG 719-738
R: GTCGAAGGTGGAAGAGTGGG 918-937
GAPDH AB038240
XM_545489
(Predicted canine PLA2R)
Full length PLA2R
Partial PLA2R
Podocin
LC049956
XM_547443.2
Nephrin
Synaptopodin
XM_541685
XM_536465.5
Table 4. Primers for seqncing canine PLA2R
Primer sequence (5’-3’) Location
1 GTAATACGACTCACTATAGGGC T7
2 CAGATGGTGGAAGCATTTGTGA 563-584
3 CATTTTTGCCAAGTGCCTGGA 1109-1129
4 CTGAGGGACGCTGGAAAGTT 1556-1575
5 ACAGGAGAAAACGGAGCAGG 2055-2074
6 GAGCGCTATCAAAGTATGGTGT 2699-2720
7 TTCCTCTCTGTGCTTTGCTATC 3299-3320
8 TGAGGCTGCTCATGAATTTTGC 3927-3948
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Table 5. Comparison of amino acid sequences 
between canine PLA2R and several animals. 
Animals Human Cat  Mouse Rat 
         % 
Full sequence 86 92 74 73 
RICIN 85 89 78 70 
FN2 94 92 73 78 
CLECT1 86 92 75 75 
CLECT2 85 91 73 77 
CLECT3 88 92 78 78 
CLECT4 98 98 89 89 
CLECT5 80 87 67 68 
CLECT6 90 96 82 79 
CLECT7 89 99 76 77 
CLECT8 88 93 77 73 
Transmembrane 
75 90 62 58 
 region 
Cytoplasmic 
80 93 69 64 
domain 
RICIN; ricin-type beta-trefoil; FN2, 
fibronectin type II domain; CLECT, C-type 
lectin like domains. 
Accession Number of PLA2R protein: 
NP_031392 (Human), XP_006935367(cat), 
NP_032893(mouse), NP_001094307(rat) 
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Fig. 2. Gene structure and tissue distribution of canine PLA2R. (A) RT-PCR for full 
length PLA2R using two different forward primers; F1 is specific for the 5’ un-
translated region of feline PLA2R, which has high homology among mammals; F2 is for 
the 5’ terminal CDS of predicted canine PLA2R. (B) Comparison of the deduced amino-
acid sequence of canine PLA2R in the N-terminal region with the predicted canine 
PLA2R sequence in Genbank (Accession Number: XM_545489) and those of human 
PLA2R (NP_031392).  In the shaded region, the sequence determined in this study was 
completely different from the predicted PLA2R amino acid sequence in Genbank. *The 
sequence obtained in this study. (C) The predicted schema of the PLA2R protein. 
RICIN; ricin-type beta-trefoil; FN2, fibronectin type II domain; CLECT, C-type lectin 
like domains. (D) RT-PCR for the partial canine PLA2R sequence in various organs. 
cDNA was prepared from heart (He), lung (Lu), liver (Li), spleen (Sp), stomach (St), 
* 
* 
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pancreas (Pa), small intestine (Si), colon (Co), uterus (Ut), ovary (Ov), testis (Te), brain 
(B), lymph node (LN), renal cortex (Rc), renal medulla (Rm), and isolated glomeruli 
(G). GAPDH cDNA was amplified as an internal control.   
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Fig. 3. Expression of PLA2R protein and mRNA in canine renal tissue. 
Immunofluorescence staining (A) and in situ hybridization (B). The expression of 
PLA2R protein (red) was observed along the capillary walls in the glomeruli (A). The 
expression of PLA2R mRNA (red dots; arrow heads) was observed in glomerulus (B). 
Bar, 30 µm. 
  
  
 BA
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Fig. 4. Localization of PLA2R protein in glomeruli. Confocal images of PLA2R (A, D, 
G and J), podocin (B and E), vimentin (H), type IV collagen (K), and merged images of 
PLA2R and podocin (C and F), vimentin (I) or type IV collagen (L). PLA2R colocalized 
with podocin along the glomerular capillary wall (A to F), but not with vimentin and 
type IV collagen, and was localized between vimentin (G to I) and type IV collagen (J 
to L). Bar, 50 µm (C) and 4 µm (L).
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Fig. 5. Immunofluorescence for PLA2R in cases of glomerular disease. 
In two MN cases (No.3 and No.4), increased staining for PLA2R along the glomerular 
capillary walls was identified but not in other three cases (No.6-8). In other glomerular 
disease such as membranoproliferative glomerular nephritis and non-immune-mediated 
glomerular nephropathy, increased expression of PLA2R was not observed. 
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Chapter 3 
 
Establishment of the primary culture method for canine podocyte 
and detection of expression of PLA2R in primary cultured 
podocytes 
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Introduction 
Podocytes are the highly differentiated epithelial cells covering with GBM and form 
particular ultrastructure, foot process and slit diaphragm. These particular structures 
have a central role of glomerular selective filtration and loss of these specific structures 
in various pathological conditions profoundly associates with protein leakage from 
glomerular capillary walls [38]. 
In veterinary medicine, several researchers investigated canine glomeruli using tissue 
samples and showed normal expression of some podocyte specific markers and altered 
expression in various pathological conditions in common with human and experimental 
animals [24, 31]. However, there is no in vitro research report using canine cultured 
glomerular podocytes because of the lack of culture methods for canine podocytes. 
Podocyte cell culture derived from human, mice and rat glomeruli has been used in 
many studies aimed for elucidating their physiological and pathophysiological 
characteristics. The methods for primary podocyte culture are relatively convenient and 
well-established methods in rodents [29, 41]. Also, primary cultured podocytes growing 
out from isolated glomeruli are assumed to retain their in vivo phenotype. 
In the previous chapter, the author revealed glomerular expression of PLA2R. However, 
strictly speaking, the expression in podocyte is still unproven. Considering the 
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mechanism of in situ IC formation in idiopathic MN, it is important to prove exactly 
podocyte expression of PLA2R. 
The object in this chapter is to establish the method of podocyte primary culture of 
dogs and to reveal the expression of PLA2R in the cultured podocyte. 
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Materials and Methods 
Animals  
Renal tissues were obtained from three 12 month-old male and beagles. The detailed 
information of the animals was described in chapter 2. All dogs were purchased from a 
laboratory animal breeding and supply company (Kitayama Labes Co, Ltd, Nagano, 
Japan) and confirmed to be healthy by physical examination. The animals were used for 
clinical education and euthanized in accordance with the guidelines approved by the 
Animal Research Committee of Azabu University (No. 100408-3) 
 
Primary culture of podocytes 
The method used for the primary culture of podocytes was based on a method for rat 
kidney [29]. Canine kidneys were enucleated with the renal artery, veins, and ureter. A 
21-gauge butterfly needle was inserted into the renal artery and the kidney was perfused 
with 20 ml PBS (pH 7.2, 0.01M) and 30 ml PBS containing 36 mg of iron powder (φ6 
µm) (Wako). The renal cortical tissue was then cut into 1-2 mm cubes in Hanks’ 
balanced salt solution (HBSS; Invitrogen). The tissues were digested in HBSS 
containing 1 mg/ml collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) 
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and 0.2 mg/ml deoxyribonuclease I (Roche Diagnostics GmbH) at 37 °C for 60 min 
with gentle agitation. The collagenase-digested tissues were gently pressed through a 
250 µm tissue strainer (Thermo Fisher Scientific, Basingstoke, United Kingdom) using 
a flattened pestle. Glomeruli containing iron powder in the tissue suspension were 
gathered using a magnetic particle concentrator (Dynal AS, Oslo, Norway) and washed 
at least four times with PBS. Finally, collected glomeruli were suspended in a suitable 
amount (approximately 12 ml) of PBS and the suspension was poured onto a 70 µm cell 
strainer (BD Biosciences, Stockholm, Sweden) and glomeruli remaining on the cell 
strainer were carefully collected. During the procedure, kidney tissues were maintained 
at 4 °C, except during the collagenase digestion. 
Isolated glomeruli were seeded on type I collagen-coated culture dishes or glass 
coverslips (Asahi techno glass, Tokyo, Japan) in Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (D-MEM:F-12, 1:1; Invitrogen) containing 5% fetal bovine 
serum (FBS; Hana-nesco Bio., Tokyo, Japan) supplemented with 0.5% Insulin-
Transferrin-Selenium-A (ITS-A) liquid media supplement (Invitrogen) and 1% 
Antibiotic-Antimycotic liquid (Invitrogen). IF was performed after incubation at 37°C 
in a humidified incubator with 5% CO2 for three days. For subculture of primary 
cultured podocytes, the cellular outgrowths obtained following three days of incubation 
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were detached using a trypsin ethylenediaminetetraacetic acid (EDTA) solution 
containing 2 g Difco™ Trypsin 250 (BD Biosciences) and 0.4 mg EDTA, disodium salt, 
dihydrate in 200 ml of 0.01 M PBS, pH 7.2, passed through a 40-µm sieve (BD 
Biosciences) to remove the remaining glomerular cores, and the filtered cells were 
gathered by centrifugation at 1000 × g. The obtained cells were then cultured on 
collagen I-coated dishes for 1 day and processed for RT-PCR or western blotting (WB) 
preparation. 
 
Immunofluorescence 
To confirm that the cultured cells express PLA2R and podocyte specific markers 
(podocin, nephrin and synaptopodin), immunocytochemical experiment was performed. 
For immunocytochemical experiment, cultured podocytes were fixed in acetone for 10 
min at -20 °C (goat PLA2R, podocin, nephrin and synaptopodin) or methanol for 5 min 
at 4 °C (mouse PLA2R, vWF, and Iba-1). The staining procedure and equipment were 
described in chapter 2.  
 
Reverse Transcriptase Polymerase Chain Reaction using cultured podocytes 
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To confirm that the cultured cells express PLA2R and podocyte specific markers 
(podocin, nephrin and synaptopodin) RT-PCR was performed. Total RNA was 
extracted from cultured podocytes using the RNeasy Plus Micro Kit (Qiagen, Hilden, 
Germany). First-strand cDNA was obtained from the total RNA using a Sensiscript RT 
kit (Qiagen) with random primers (Invitrogen), in the presence of RNasin ribonuclease 
inhibitor (Promega, Madison, Wisconsin). Table 2 summarizes the primer sequences 
used in this study. The primer sequences were designed based on the predicted mRNA 
sequences of Canis lupus familiaris nephrosis 1, congenital, Finnish type (nephrin) 
(NCBI database, accession number: XM_541685), Canis lupus familiaris nephrosis 2, 
idiopathic, steroid-resistant (podocin) (XM_547443.2), Canis lupus familiaris 
synaptopodin  (XM_536465.5).  PCR reactions were performed as follows: denaturation 
at 94°C for 2 min; 40 cycles of denaturation at 98°C for 10 s, annealing at 64°C for 30 s, 
and extension at 68°C for 30 s; and a final extension step at 68°C for 30 s. The other 
information for PCR was described in chapter 2. 
 
Isolation of glomeruli for western blotting 
Isolation of glomeruli for WB was performed according to the above description in 
chapter 2.  
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Western blotting  
To confirm that the cultured cells express PLA2R and podocin, WB was performed. 
The proteins from isolated glomeruli and cultured podocytes were extracted and lysed in 
RIPA buffer (consisting of 0.1% sodium dodecyl sulphate [SDS], 1% NP-40, 150 mM 
NaCl and 0.5% sodium deoxycholate in 50 mM Tris-HCl, pH 7.4) with Protease 
Inhibitor Cocktail Set I (Wako, Osaka, Japan) and protein concentrations were assayed 
using the Lowry method (DC Protein Assay, BioRad, Hercules, California). For SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), samples were mixed with an equal 
volume of sample buffer containing 10% beta-mercaptoethanol (5% final concentration) 
and boiled for 5 min. Proteins (10 µg/lane) were run on 10% polyacrylamide slab gels 
and transferred to polyvinylidene fluoride membranes. The membranes were blocked 
with 10% skimmed milk in PBS with 0.1% Tween 20 for 1 h at room temperature and 
incubated overnight at 4 °C with the mouse anti-PLA2R (1 in 700 dilution) or the rabbit 
anti-podocin (1 in 1000) antibodies diluted in Immuno-Enhancer Reagent A (Wako). 
After washing, the membranes were incubated with a horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG antibody (Dako Cytomation, Glostrup, Denmark; 1 in 
2000 dilution) or HRP-conjugated goat anti-rabbit IgG antibody (Dako Cytomation; 1 in 
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2000 dilution) diluted in Immuno-Enhancer Reagent B (Wako) for 1 hr at room 
temperature. Immunoreactivity was visualized using Luminata
™ 
Forte Western HRP 
Substrate (Millipore, Temicula, California, USA) and detected using an LAS4000 (GE 
Healthcare Japan Co., Ltd., Tokyo, Japan). 
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Results 
Podocytes outgrowth from isolated glomeruli and expression of podocyte-specific 
proteins in cultured podocytes 
A number of isolated glomeruli were collected and all of the isolated glomeruli were 
decapsulated. However, a low rate of blood vessel and tubular contamination was 
observed (3.3 ± 1.5 %; n = 3). Cellular growth of podocytes from isolated glomeruli 
was first detected within 2 days and became prominent by 3-4 days in culture (Fig. 6). 
The podocyte morphology was irregular, often exhibiting arborization with long 
cytoplasmic processes, and multinucleation. Their morphology was identical to that of 
primary cultured rat podocytes described in previous reports [29, 45]. Also a small 
number of fibroblast and tubular epithelial cells proliferation from contaminated blood 
vessel and tubules were sometimes observed. 
These cultured cells also showed distinct expression of the podocyte specific proteins 
(nephrin, podocin, and synaptopodin) by IF (Fig. 7A). Synaptopodin exhibited most 
characteristic staining pattern, stress fiber-like appearance and cross striation. The 
cultured cells expressed nephrin and podocin in the cytoplasm and marginal region. 
Gene expression of these proteins in the primary cultured podocytes was also confirmed 
by RT-PCR (Fig. 7B). In WB, the specific band for podocin with an extra band was 
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observed. None of the outgrowing cells showed positive staining for von Willebrand 
factor (an endothelial marker) or ionized calcium binding adaptor molecule 1 (a 
macrophage markers) (data not shown).  
 
Expression of PLA2R in cultured podocytes 
The cultured cells also showed distinct positive staining for PLA2R by IF using 
different antibodies. The positive staining was observed to be prominent in the 
cytoplasm and marginal region (Fig. 8A). Expression of PLA2R in the primary cultured 
podocytes was also confirmed by RT-PCR and WB (Fig. 8B and C). A distinct single 
band was observed in WB for cultured podocytes.  
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Discussion 
The author succeeded in effective isolation of glomeruli from canine kidney by 
modifying an isolation method established for rat in previous report [29, 41]. In 
previous reports, it is considered as a good preparation when 95% of the cellular 
constituents in isolated tissue is glomeruli [41] and the samples obtained in the present 
study was assumed to be good preparation according to this criteria. 
Cultured podocytes in the present study expressed several podocyte-specific markers, 
including nephrin, podocin and synaptopodin. Consistent with previous reports, nephrin 
and podocin was localized in the cytoplasm and cell surface in cultured podocytes in 
this study [12, 26, 29]. The cytoplasmic expression pattern of nephrin and podocin in 
cultured podocytes is inconsistent with the expression pattern observed in glomeruli in 
the tissue section, and might related to the morphological features of cultured podocytes, 
which lack foot processes and slit-diaphragms, or unusual intracellular transport of 
these proteins in the in vitro environment. 
Considering the mechanism of in situ IC formation in idiopathic MN, the localization 
of the target antigen on podocyte cell membrane is important. The marginal localization 
of PLA2R in canine cultured podocytes consistent with that of foot process-associated 
proteins (nephrin and podocin) is also an important finding supporting this possibility, 
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because the binding of circulating antibodies against PLA2R on the basal surface of the 
podocyte foot processes is assumed to be the mechanism for subepithelial deposition of 
IC which is a characteristic feature in idiopathic MN, as suggested by various reports 
using experimental rat models of MN [19, 27] and human neonatal MN [10]. 
The cultured podocytes have been used in previous research for idiopathic MN. 
Meyer-Schwesinger et al. established a new mouse model of MN in which sheep anti 
serum against murine cultured podocytes caused subepithelial IC formation in the 
glomeruli of injected mice and suggested some candidate auto-antigens in podocytes in 
the models [34]. Moreover, commercial detection kit (Euroimmun AG) for anti- PLA2R 
autoantibodies in patient serum of human idiopathic MN is an IF test using cultured 
HEK293 cells transfected with the PLA2R [40]. Yangbin et al. reported that the 
increased levels of serum sPLA2-IB (a subtype of sPLA2) in MN patients enhanced 
glomerular expression of PLA2R [37]. Furthermore, Pan et al. demonstrated using 
immortalized human cultured podocytes that the interaction between sPLA2-IB and 
PLA2R stimulate podocyte apoptosis through activating ERK1/2 and cytosolic PLA2α, 
as well as through increasing podocyte arachidonic acid content. However, given the 
high degree of specialization and complex cytoarchitecture of podocytes, it is more 
significant to explain the involvement of PLA2R in podocyte dysfunction by 
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investigating the expression of podocyte specific proteins or the reconstruction of actin 
cytoskeleton network closely linked to podocyte functions, rather than detection of 
apoptosis [1, 26, 35, 44].  For instance, Yasuno et al. revealed podocyte injury induced 
by angiotensin II by evaluating reorganization of F-actin fiber in subcultured podocyte 
derived from Osborn Mendel rats, showing progressive spontaneous 
glomerulonephropathy [46]. Therefore, the primary culture of canine podocytes may be 
useful for evaluation the effect of sPLA2 and PLA2R on podocyte or detection of 
autoantibodies in serums in affected dogs. In addition, several questions about the direct 
effect of binding of autoantibodies against PLA2R, such as whether the binding of anti-
PLA2R autoantibodies itself can cause podocyte injury or enhanced expression of 
PLA2R in podocytes, could be evaluated by using canine podocytes. Therefore, in-vitro 
method demonstrated in this study may contribute to advance research about podocytes 
or glomerular diseases in dogs. 
In this chapter, the author demonstrated the method of canine podocyte primary culture. 
The primary cultured cells expressed PLA2R in addition to several podocyte-specific 
proteins. This is the first study of primary cultured footed mammalian podocytes 
expressing PLA2R. The result in this chapter did prove the expression of PLA2R in 
podocyte suggested by the results of tissue section in previous chapter. The in-vitro 
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experiment provided from this method may contribute to progression of investigation 
for canine glomerular disease including MN. 
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Figures and Tables 
 
a
dc
b
 
Fig. 6. Phase-contrast microscopy of isolated canine glomeruli and cellular growth of 
podocytes. Phase-contrast microscopy of isolated glomeruli from canine renal tissue (A) 
and their cellular outgrowths after 2 days (B) and 3 days (C and D) in culture. *Isolated 
glomerulus, Bar = 100 µm. 
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Fig. 7. Expression of podocyte markers in primary cultured canine podocytes. 
Immunofluorescence for podocyte-specific proteins (synaptopodin, podocin and 
nephrin) (A), reverse transcriptase polymerase chain reaction (RT-PCR) for podocyte-
specific markers (podocin, synaptopodin and nephrin) (B), and western blotting for 
podocin protein (C) in canine primary cultured podocytes. Rabbit and goat IgG: 
negative control. Arrowheads: expression on marginal region. Asterisk: Isolated 
glomerulus. Bar = 25 µm. 
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Fig. 8. Expression of PLA2R in primary cultured canine podocytes. (A) 
Immunofluorescence for PLA2R staining (A), reverse transcriptase polymerase chain 
reaction (RT-PCR) for PLA2R1 and GAPDH (B), and Western blotting for PLA2R 
protein (C) in primary cultured canine podocytes. Mouse IgG: negative control. 
Arrowheads: expression on marginal region. Asterisk: Isolated glomerulus. Bar = 25 
µm. 
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Conclusion 
The author revealed the expression of PLA2R in canine podocytes and, the 
ultrastructural features observed in some MN dogs were shared with human idiopathic 
MN associated with PLA2R. Conclusion is summarized as follows.   
1. Canine MN showed two different deposition patterns of dense deposit in the 
glomeruli resembling human idiopathic or secondary MN. This may suggest the 
presence of different pathogenesis in canine MN as suspected in human MN. 
2. Canine PLA2R obtained from the glomeruli has high homology and common 
extracellular structures with human PLA2R.  
3. PLA2R is expressed in canine podocyte and distributed on the foot process in tissue 
sections. This is important finding suggesting the possibility of dogs as an animal model 
of human idiopathic MN. Because PLA2R is not expressed in the podocytes of rodents, 
rabbits and no experimental or spontaneous animal models for idiopathic MN have been 
established, so far.  
4. The increased expression of PLA2R, which is feature of human idiopathic MN 
associated with PLA2R, demonstrated in some of MN dog cases with idiopathic 
ultrastructural pattern of dense deposit. These results may support the author’s 
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hypothesis that some canine MN cases are autoimmune disease associated with PLA2R 
as an autoantigen expressed in podocyte. 
5. The primary culture method for canine podocyte expressed several podocyte specific 
proteins was established. The in vitro experiment provided from this method may 
contribute to progression of investigation for canine glomerular disease including MN. 
 
In this study, the author suggested that some canine MN might be associated with 
PLA2R, but it was not proven. As future subject to confirm the author’s hypothesis, 
detection of anti-PLA2R autoantibodies in the serum of affected dogs is most important. 
In human medicine, technologies applied to detect anti-PLA2R autoantibody such as 
WB using isolated glomeruli [2, 17, 36, 39], IF test using cultured HEK293 cells 
transfected with the PLA2R [5, 21-23] and ELISA using recombinant PLA2R obtained 
from the same cells [5, 21, 28], were established. The establishment of these 
examination tools for dogs and suitable and routine storage of the serum from dogs 
given renal biopsy could contribute to the detection of autoantibodies in the serum from 
dogs with MN. Also, the establishment of an animal model caused by the immunization 
with PLA2R or injection of anti-PLA2R antibodies made from other animals may prove 
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that the circulating anti-PLA2R antibodies can cause MN. As identified in this study, 
dogs may be a candidate animal for the useful model of human idiopathic MN. 
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